查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1535303

真實世界證據解決方案市場規模、份額、預測、趨勢分析：按組件、按應用、按最終用戶 - 到 2031 年的全球預測

Real-world Evidence Solutions Market Size, Share, Forecast, & Trends Analysis by Component (Datasets [Clinical, Claims, Pharmacy], Services) Application (Market Access, Drug Development & Approvals, PMS), and End User - Global Forecast to 2031
出版日期: | 出版商: Meticulous Research | 英文 254 Pages | 訂單完成後即時交付

價格

2023 年全球現實世界證據 (RWE) 解決方案市場規模為 26.2 億美元。該市場預計將從 2024 年的 29.4 億美元增至 2031 年的 63.7 億美元，2024-2031 年預測期間複合年增長率為 11.7%。

該報告基於全面的一手和二手研究以及對市場情景的深入分析，提供了該行業的關鍵驅動因素、限制因素、挑戰和機遇。該市場的推動因素包括慢性病的增加、藥物開發的延遲以及相關的開發成本的增加、對個人化醫療保健的日益關注、向基於價值的醫學的轉變以及藥物開發和商業化，其中包括擴大真實藥物的採用。例如，IQVIA 於 2024 年 6 月宣布推出 One Home for Sites。此數位平台可作為臨床試驗場所進行臨床試驗所需的所有關鍵系統和任務的儀表板。

此外，新興國家和對端到端 RWE 服務的日益關注正在為現實世界的解決方案市場創造巨大的成長機會。然而，市場擴張可能會因不願依賴實地研究和缺乏數據收集品質控製而受到限制。此外，缺乏開發 RWE 的標準化方法以及對資料隱私和安全的擔憂給在該市場運營的公司帶來了重大挑戰。

按組件劃分，資料集細分市場預計將在 2024 年佔據 RWE 解決方案市場的最大份額。 RWE 資料集源自於與現實世界中不同人群的患者結果相關的各種來源。該解決方案提供了有關未滿足的需求以及對患者和醫療保健系統的財務和臨床影響的深刻資訊。此外，它基於更大的數據集、更低的成本和更有效的臨床試驗管理。

從應用來看，市場准入和報銷/覆蓋決策部分預計將在 2024 年佔據 RWE 解決方案市場的最大份額。 RWE 的市場准入解決方案利用預測分析和數據驅動的洞察力，對醫療產品的有效性和價值進行全面評估，支持基於價值的定價策略，並推動帶來有利的報銷結果。龐大的市場份額是由醫療保健成本上升、監管機構對RWE 的接受度提高、承保決策中臨床價值證據的重要性日益增加以及常規臨床環境和異質患者群體中治療效果的補充數據的可用性推動的。

在最終用戶中，製藥、生物技術和醫療器材公司領域預計將在 2024 年佔據 RWE 解決方案市場的最大份額。收集即時臨床後藥物數據、監測藥物反應、擴大 RWE 的使用以證明臨床試驗之外新療法的價值、加快藥物測試和延長批准時間等幾個變量佔了很大份額。

對全球 RWE 解決方案市場區域狀況的詳細分析提供了五個主要區域（北美、歐洲、亞太地區、中東和非洲以及拉丁美洲）的詳細定性和定量見解。涵蓋各地區主要國家。

到 2024 年，北美預計將佔據全球 RWE 解決方案市場的最大份額，其次是歐洲、亞太地區、拉丁美洲以及中東和非洲。北美的顯著份額是由慢性病發病率上升、更嚴格的藥物審批指南、21世紀的治療方法、電子數據集的廣泛使用、強大的醫療保健行業以及醫療保健中大數據的使用推動的。包括擴大

調查範圍:

真實世界證據解決方案市場評估：按組成部分

  • 資料集
    • 個別資料集
  • EMR/EHR/臨床資料
  • 申請資料
  • 藥局資料
  • 產品/疾病登記資料
  • 基因資料
  • 其他的個別資料集
    • 整合資料集
  • 諮詢服務

注意：其他單獨的資料集包括從行動裝置、穿戴式裝置和社群媒體產生的資料。

真實世界證據解決方案市場評估：按應用劃分

  • 市場進入和償付/適用範圍的決策
  • 醫藥品開發·核准
    • 腫瘤學
    • 神經學
    • 免疫學
    • 心血管疾病
    • 其他的治療領域
  • 上市後監測
  • 醫療設備的開發與核准
  • 其他的用途

註1：其他治療領域包括傳染病、肌肉骨骼疾病、皮膚病、呼吸系統疾病。

註 2：其他用途包括監管和臨床決策。

真實世界證據解決方案市場評估：按最終用戶

  • 製藥，生物科技，醫療設備企業
  • 醫療保健付款者
  • 醫療保健供應商
  • 其他的終端用戶

註：其他最終使用者包括學術研究機構、病患權益團體、監管機構和健康科技評估機構。

真實世界證據解決方案市場評估：按地區

  • 北美
  • 美國
  • 加拿大
  • 歐洲
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙
  • 瑞士
  • 比利時
  • 其他歐洲(RoE)
  • 亞太地區(APAC)
  • 中國
  • 日本
  • 印度
  • 韓國
  • 台灣
  • 新加坡
  • 澳洲
  • 其他亞太地區(RoAPAC)
  • 南美
  • 巴西
  • 墨西哥
  • 其他南美國家(RoLATAM)
  • 中東·非洲

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場洞察

  • 概要
  • 市場成長的要素
    • 市場動態
      • 促進因素
        • 越來越重視個人化醫療保健
        • 藥物開發的延遲以及相關的開發成本增加
        • 慢性疾病增加
        • 轉向以價值為基礎的醫療保健
        • 醫療保健領域大數據的激增
      • 阻礙因素
        • 不願意進行實際的臨床試驗
      • 機會
        • 新興國家
        • 日益關注端到端 RWE 服務
      • 課題
        • 缺乏 RWE 開發的標準化研究方法
    • 要素分析
  • 主要市場趨勢
    • RWE產業上人工智慧的引進
      • 人工智慧技術在以下領域的應用不斷成長：
        • 臨床試驗設計
        • 患者豐富和招募的建模和預測
        • 臨床試驗醫療機構的選擇
        • 病患監測與管理、藥物順從性和保留率
        • 使用人工智慧進行臨床試驗分析
        • 透過策略夥伴關係和協作外包人工智慧解決方案
        • 利用人工智慧解決方案進入市場
        • 使用人工智慧解決方案進行上市後監控
    • 在藥物開發和商業化中越來越多地採用 RWE
    • 企業整合增加
    • 利用真實世界證據改善病患治療效果並創造價值
  • 基於人工智慧的 RWE 解決方案案例研究
    • 基於人工智慧的 RWE 解決方案，用於醫療器材上市後監控 - Huma.AI（美國）
    • 基於人工智慧的 RWE 解決方案支援藥物研發的臨床決策 - Owkin, Inc.
    • 用於市場准入的人工智慧整合 RWE 解決方案 - Medaffcon Oy（芬蘭）
    • 利用人工智慧和機器學習演算法獲得真實數據洞察 - Aetion, Inc.（美國）和 Quinten Health（法國）
    • 由人工智慧驅動的 RWE 平台用於追蹤不良事件 - Data2Life（以色列）
    • 利用 AI 支援的 RWE 解決方案預測重症監護病房病患的健康狀況 - PHASTAR（英國）
  • 法規分析
    • 概要
    • 北美
    • 歐洲
    • 亞太地區
    • 全球其他地區
  • 價格設定模式(EMR/基因/整合資料集)
    • 摘要
    • 按病患記錄付費（按數量定價）
    • 按使用量付費（基於價值的定價）
    • 年度訂閱

第5章 真實世界證據解決方案市場評估:各零件

  • 概要
  • 資料集
    • 不同的資料集
      • EMR/EHR/臨床資料
      • 申請資料
      • 藥局資料
      • 產品/疾病登記資料
      • 基因資料
      • 其他的個別資料集
    • 整合資料集
  • 諮詢與分析

第6章 真實世界證據解決方案市場評估:各用途

  • 概要
  • 市場進入和償付/適用範圍的決策
  • 醫藥品開發·核准
    • 癌症領域
    • 神經學
    • 免疫學
    • 心血管疾病
    • 其他的治療領域
  • 上市後監測
  • 醫療設備開發·核准
  • 其他的用途

第7章 真實世界證據解決方案市場評估:各終端用戶

  • 概要
  • 製藥，生物科技，醫療設備企業
  • 醫療保健payer
  • 醫療保健供應商
  • 其他的終端用戶

第8章 真實世界證據解決方案市場評估:各地區

  • 概要
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞士
    • 比利時
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 台灣
    • 新加坡
    • 其他亞太地區
  • 南美
    • 巴西
    • 墨西哥
    • 其他南美國家
  • 中東·非洲

第9章 競爭情形

  • 簡介
  • 主要成長策略
  • 競爭基準
  • 競爭儀表板
    • 產業領導者
    • 市場差異化要素
    • 領先企業
    • 新興企業
  • 市場佔有率分析
    • IQVIA Holdings Inc.(U.S.)
    • Icon plc(IRELAND)
    • Thermo Fisher Scientific Inc.(U.S.)

第10章 企業簡介

  • IQVIA Holdings, Inc.
  • Icon plc
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche Ltd
  • Oracle Corporation
  • Elevance Health, Inc.
  • Clinigen Group Plc
  • Cognizant Technology Solutions Corporation
  • Revvity, Inc.
  • SAS Institute Inc.
  • Parexel International Corporation
  • Healthverity, Inc.

第11章 附錄

Product Code: MRHC - 104253

Real-world Evidence Solutions Market Size, Share, Forecast, & Trends Analysis by Component (Datasets [Clinical, Claims, Pharmacy], Services) Application (Market Access, Drug Development & Approvals, PMS), and End User-Global Forecast to 2031

The global RWE solutions market was valued at $2.62 billion in 2023. This market is expected to reach $6.37 billion by 2031 from an estimated $2.94 billion in 2024, at a CAGR of 11.7% during the forecast period of 2024-2031.

Following a comprehensive primary & secondary study and an in-depth analysis of the market scenario, this report provides the key drivers, constraints, challenges, and opportunities of the industry. This market is driven by the growing incidence of chronic diseases, delays in drug development and the consequent increase in development costs, the rising focus on personalized healthcare, a shift toward value-based care, and the growing adoption of real-world evidence solutions in drug development & commercialization. For instance, IQVIA introduced One Home for Sites in June 2024. This digital platform serves as a dashboard for all the essential systems and tasks needed by a clinical research site to conduct clinical trials.

Furthermore, emerging economies and a rising focus on end-to-end RWE services provide significant growth opportunities for the real-world solutions market. However, the market's expansion may be constrained by the unwillingness to rely on real-world research and the absence of quality control in data collection. Additionally, the lack of standardized methodologies for developing RWE and data privacy and security concerns pose a major challenge for the players operating in this market.

Among components, in 2024, the datasets segment is expected to account for the largest share of the RWE solutions market. RWE datasets originate from a range of sources related to patient outcomes in diverse populations in real-world contexts. With regard to unfulfilled needs and the financial and clinical effects on patients and healthcare systems, this solution offers insightful information. Additionally, it bases results on far larger data sets, lower expenses, and more effective clinical trial management.

Among applications, in 2024, the market access & reimbursement/coverage decisions segment is expected to account for the largest share of the RWE solutions market. Using predictive analysis and data-driven insights, RWE solutions for market access enable a comprehensive assessment of a medical product's efficacy and value, which can support value-based pricing strategies and result in favorable reimbursement outcomes. The significant market share is ascribed to several factors, including escalating healthcare expenses, growing regulatory body acceptance of RWE, expanding significance of clinical value evidence in coverage determinations, and the availability of supplementary data regarding treatment efficacy in routine care environments and heterogeneous patient cohorts.

Among end users, in 2024, the pharmaceutical, biotechnology, and medical device companies segment is expected to account for the largest share of the RWE solutions market. Several variables, including the growing use of RWE to gather real-time post-trial data about medications, monitor drug reactions, and prove the worth of newly created therapies outside of clinical trials, as well as expedited drug trials and extended approvals, are responsible for a substantial share of the segment.

An in-depth analysis of the global RWE solutions market's geographical scenario provides detailed qualitative and quantitative insights for the five major geographies (North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America). It covers the major countries in each region.

In 2024, North America is expected to account for the largest share of the global RWE solutions market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The substantial share of North America can be attributed to various factors, including the rising incidence of chronic illnesses, stricter guidelines for medication approvals, the 21st Century Cures Act, the broad accessibility of electronic datasets, a firmly established healthcare industry, and the growing application of big data in healthcare.

The key players operating in the global RWE solutions market are IQVIA Holdings Inc. (U.S.), Elevance Health, Inc. (U.S.), ICON plc (Ireland), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Revvity, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Oracle Corporation (U.S.), SAS Institute Inc. (U.S.), Parexel International Corporation (U.S.), and HealthVerity, Inc. (U.S.).

Scope of the Report:

Real-world Evidence Solutions Market Assessment-by Component

  • Datasets
    • Disparate Datasets
  • EMR/EHR/Clinical Data
  • Claims & Billing Data
  • Pharmacy Data
  • Product/Disease Registries Data
  • Genomics Data
  • Other Disparate Datasets
    • Integrated Datasets
  • Consulting Services

Note: Other Disparate Datasets include data generated from mobile devices, wearable devices, and social media.

Real-world Evidence Solutions Market Assessment-by Application

  • Market Access & Reimbursement/Coverage Decisions
  • Drug Development & Approvals
    • Oncology
    • Neurology
    • Immunology
    • Cardiovascular Diseases
    • Other Therapeutic Areas
  • Post Market Surveillance
  • Medical Device Development & Approvals
  • Other Applications

Note: 1) Other Therapeutic Areas include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases.

2) Other Applications include regulatory and clinical decision-making.

Real-world Evidence Solutions Market Assessment-by End User

  • Pharmaceutical, Biotechnology, and Medical Device Companies
  • Healthcare Payers
  • Healthcare Providers
  • Other End Users

Note: Other end users include academic & research institutions, patient advocacy groups, regulators, and health technology assessment agencies.

Real-world Evidence Solutions Market Assessment-by Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • U.K
  • Italy
  • Spain
  • Switzerland
  • Belgium
  • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Singapore
  • Australia
  • Rest of Asia-Pacific (RoAPAC)
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLATAM)
  • Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition & Scope
  • 1.2. Market Ecosystem
  • 1.3. Currency & Limitations
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Process
  • 2.2. Data Collection & Validation Process
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
  • 2.3. Market Sizing & Forecasting
    • 2.3.1. Market Size Estimation Approach
    • 2.3.2. Growth Forecast Approach
    • 2.3.3. Market Share Analysis
  • 2.4. Assumptions For the Study

3. Executive Summary

4. Market Insights

  • 4.1. Overview
  • 4.2. Factors Affecting Market Growth
    • 4.2.1. Market Dynamics
      • 4.2.1.1. Drivers
        • 4.2.1.1.1. Rising Focus on Personalized Healthcare
        • 4.2.1.1.2. Delays in Drug Development and the Consequent Increase in Development Costs
        • 4.2.1.1.3. Growing Incidence of Chronic Diseases
        • 4.2.1.1.4. Shift toward Value-based Care
        • 4.2.1.1.5. Rapidly Growing Big Data in the Healthcare Sector
      • 4.2.1.2. Restraints
        • 4.2.1.2.1. Reluctance to Rely on Real-world Studies
      • 4.2.1.3. Opportunities
        • 4.2.1.3.1. Emerging economies
        • 4.2.1.3.2. Rising Focus on End-to-End RWE Services
      • 4.2.1.4. Challenges
        • 4.2.1.4.1. Lack of Standardized Methodologies for Developing RWE
    • 4.2.2. Factors Analysis
  • 4.3. Key Market Trends
    • 4.3.1. The Incorporation of Artificial Intelligence (AI) in the RWE Industry
      • 4.3.1.1. The Adoption of AI Technologies is Growing in the Following Areas:
        • 4.3.1.1.1. Clinical Trials Design
        • 4.3.1.1.2. Modeling and Forecasting Patient Enrichment & Recruitment
        • 4.3.1.1.3. Selecting Investigator Site
        • 4.3.1.1.4. Patient Monitoring & Managing and Medication Adherence & Retention
        • 4.3.1.1.5. AI-enabled Clinical Trial Analytics
        • 4.3.1.1.6. Outsourcing Essential AI Solutions via Strategic Partnerships & Collaborations
        • 4.3.1.1.7. Market Access Using AI Solutions
        • 4.3.1.1.8. Post-market Surveillance Using AI Solutions
    • 4.3.2. Growing Adoption of RWE In Drug Development and Commercialization
    • 4.3.3. Rising Number of Consolidations
    • 4.3.4. Improved Patient Outcomes and Value Creation from Real-World Evidence
  • 4.4. Case Studies For AI-based RWE Solutions
    • 4.4.1. AI-based RWE Solutions for Medical Device Post-market Studies - Huma.AI (U.S.)
    • 4.4.2. AI-enabled RWE Solutions to Support Clinical Decision-making in Drug Research & Development - Owkin, Inc. (France)
    • 4.4.3. AI-integrated RWE Solutions for Market Access - Medaffcon Oy (Finland)
    • 4.4.4. Leveraging Real-world Data Insights Using AI & Machine Learning Algorithms - Aetion, Inc. (U.S.) & Quinten Health (France)
    • 4.4.5. AI-powered RWE Platform to Track Adverse Events - Data2Life (Israel)
    • 4.4.6. AI-powered RWE Solutions to Predict Patients' Health at Critical Care Units - PHASTAR (U.K.)
  • 4.5. Regulatory Analysis
    • 4.5.1. Overview
    • 4.5.2. North America
    • 4.5.3. Europe
    • 4.5.4. Asia-Pacific
    • 4.5.5. Rest of the World
  • 4.6. Pricing Models (EMR/Genomic/Integrated Datasets)
    • 4.6.1. Overview
    • 4.6.2. Pay Per Patient Record (Volume-based Pricing)
    • 4.6.3. Pay Per Usage (Value-based Pricing)
    • 4.6.4. Annual Subscription

5. Real-World Evidence (RWE) Solutions Market Assessment-by Component

  • 5.1. Overview
  • 5.2. Datasets
    • 5.2.1. Disparate Datasets
      • 5.2.1.1. EMR/EHR/Clinical Data
      • 5.2.1.2. Claims & Billing Data
      • 5.2.1.3. Pharmacy Data
      • 5.2.1.4. Product/Disease Registries Data
      • 5.2.1.5. Genomics Data
      • 5.2.1.6. Other Disparate Datasets
    • 5.2.2. Integrated Datasets
  • 5.3. Consulting & Analytics

6. Real-World Evidence Solutions Market Assessment-by Application

  • 6.1. Overview
  • 6.2. Market Access & Reimbursement/Coverage Decisions
  • 6.3. Drug Development & Approvals
    • 6.3.1. Oncology
    • 6.3.2. Neurology
    • 6.3.3. Immunology
    • 6.3.4. Cardiovascular Diseases
    • 6.3.5. Other Therapeutic Areas
  • 6.4. Post-market Surveillance
  • 6.5. Medical Device Development & Approvals
  • 6.6. Other Applications

7. Real-World Evidence (RWE) Solutions Market Assessment-by End User

  • 7.1. Overview
  • 7.2. Pharmaceutical, Biotechnology, and Medical Device Companies
  • 7.3. Healthcare Payers
  • 7.4. Healthcare Providers
  • 7.5. Other End Users

8. Real-world Evidence Solutions Market Assessment-by geography

  • 8.1. Overview
  • 8.2. North America
    • 8.2.1. U.S.
    • 8.2.2. Canada
  • 8.3. Europe
    • 8.3.1. U.K.
    • 8.3.2. Germany
    • 8.3.3. France
    • 8.3.4. Italy
    • 8.3.5. Spain
    • 8.3.6. Switzerland
    • 8.3.7. Belgium
    • 8.3.8. Rest of Europe
  • 8.4. Asia-Pacific
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. South Korea
    • 8.4.5. Australia
    • 8.4.6. Taiwan
    • 8.4.7. Singapore
    • 8.4.8. Rest of Asia-Pacific
  • 8.5. Latin America
    • 8.5.1. Brazil
    • 8.5.2. Mexico
    • 8.5.3. Rest of Latin America
  • 8.6. Middle East & Africa

9. Competitive Landscape

  • 9.1. Introduction
  • 9.2. Key Growth Strategies
  • 9.3. Competitive Benchmarking
  • 9.4. Competitive Dashboard
    • 9.4.1. Industry Leaders
    • 9.4.2. Market Differentiators
    • 9.4.3. Vanguards
    • 9.4.4. Emerging Companies
  • 9.5. Market Share Analysis
    • 9.5.1. IQVIA Holdings Inc. (U.S.)
    • 9.5.2. Icon plc (IRELAND)
    • 9.5.3. Thermo Fisher Scientific Inc. (U.S.)

10. Company Profiles

  • 10.1. IQVIA Holdings, Inc.
  • 10.2. Icon plc
  • 10.3. Thermo Fisher Scientific Inc.
  • 10.4. F. Hoffmann-La Roche Ltd
  • 10.5. Oracle Corporation
  • 10.6. Elevance Health, Inc.
  • 10.7. Clinigen Group Plc
  • 10.8. Cognizant Technology Solutions Corporation
  • 10.9. Revvity, Inc.
  • 10.10. SAS Institute Inc.
  • 10.11. Parexel International Corporation
  • 10.12. Healthverity, Inc.

11. Appendix

  • 11.1. Available Customization
  • 11.2. Related Reports

LIST OF TABLES

  • Table 1 Total Cost Per Study, by Phase and Therapeutic Area (USD Million)
  • Table 2 Sources of Healthcare Data
  • Table 3 Number of People aged 65 years or Over, by Region, 2019 vs. 2050 (Million)
  • Table 4 Strategic Developments of Key Players Related to the Integration of AI into RWE Solutions
  • Table 5 Real-world Evidence Status in Latin America
  • Table 6 Observed Indicative Prices of Real-world Data by Type (USD Per Patient Record)
  • Table 7 Global Real-world Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 8 Global RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 9 Global RWE Datasets Market, by Country/Region, 2022-2031 (USD Million)
  • Table 10 Global RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 11 Global RWE Disparate Datasets Market, by Country/Region, 2022-2031 (USD Million)
  • Table 12 Global EMR/EHR/Clinical Data Market, by Country/Region, 2022-2031 (USD Million)
  • Table 13 Global Claims and Billing Data Market, by Country/Region, 2022-2031 (USD Million)
  • Table 14 Global Pharmacy Data Market, by Country/Region, 2022-2031 (USD Million)
  • Table 15 Global Product/Disease Registries Data Market, by Country/Region, 2022-2031 (USD Million)
  • Table 16 Global Genomics Data Market, by Country/Region, 2022-2031 (USD Million)
  • Table 17 Global Other Disparate Datasets Market, by Country/Region, 2022-2031 (USD Million)
  • Table 18 Global RWE Integrated Datasets Market, by Country/Region, 2022-2031 (USD Million)
  • Table 19 Global RWE Consulting & Analytics market, by Country/Region, 2022-2031 (USD Million)
  • Table 20 Global Real-world Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 21 Global RWE Solutions Market for Market Access & Reimbursement/Coverage Decisions, by Country/Region, 2022-2031 (USD Million)
  • Table 22 Global RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 23 Global RWE Solutions Market for Drug Development & Approvals, by Country/Region, 2022-2031 (USD Million)
  • Table 24 Global RWE Solutions Market for Oncology, by Country/Region, 2022-2031 (USD Million)
  • Table 25 Global RWE Solutions Market for Neurology, by Country/Region, 2022-2031 (USD Million)
  • Table 26 Global RWE Solutions Market for Immunology, by Country/Region, 2022-2031 (USD Million)
  • Table 27 Estimated Medical Costs Associated with Cardiovascular Diseases (2020-2030) (USD Billion)
  • Table 28 Global RWE Solutions Market for Cardiovascular Diseases, by Country/Region, 2022-2031 (USD Million)
  • Table 29 Global RWE Solutions Market for Other Therapeutic Areas, by Country/Region, 2022-2031 (USD Million)
  • Table 30 Global RWE Solutions Market for Post-market Surveillance, by Country/Region, 2022-2031 (USD Million)
  • Table 31 Global RWE Solutions Market for Medical Device Development & Approvals, by Country/Region, 2022-2031 (USD Million)
  • Table 32 Global RWE Solutions Market for Other Applications, by Country/Region, 2022-2031 (USD Million)
  • Table 33 Global Real-world Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 34 Global RWE Solutions Market for Pharmaceutical, Biotechnology, and Medical Device Companies, by Country/Region, 2022-2031 (USD Million)
  • Table 35 Global RWE Solutions Market for Healthcare Payers, by Country/Region, 2022-2031 (USD Million)
  • Table 36 Global RWE Solutions Market for Healthcare Providers, by Country/Region, 2022-2031 (USD Million)
  • Table 37 Global RWE Solutions Market for Other End Users, by Country/Region, 2022-2031 (USD Million)
  • Table 38 Global RWE Solutions Market, by Country/Region, 2022-2031 (USD Million)
  • Table 39 North America: RWE Solutions Market, by Country, 2022-2031 (USD Million)
  • Table 40 North America: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 41 North America: RWE Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 42 North America: RWE Disparate Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 43 North America: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 44 North America: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 45 North America: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 46 U.S.: RWE Solutions Market, by component, 2022-2031 (USD Million)
  • Table 47 U.S.: RWE Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 48 U.S.: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 49 U.S.: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 50 U.S.: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 51 U.S.: RWE Solution, by End User, 2022-2031 (USD Million)
  • Table 52 Canada: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 53 Canada: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 54 Canada: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 55 Canada: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 56 Canada: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 57 Canada: RWE Solution, by End User, 2022-2031 (USD Million)
  • Table 58 EUROPE: RWE solutions Market, by Country/Region, 2022-2031 (USD Million)
  • Table 59 Europe: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 60 Europe: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 61 Europe: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 62 Europe: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 63 Europe: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 64 Europe: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 65 U.K.: Conferences and Workshops on Real-world Evidence Solutions
  • Table 66 U.K.: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 67 U.K.: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 68 U.K.: RWE Disparate Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 69 U.K.: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 70 U.K.: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 71 U.K.: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 72 Conferences, Symposia, and Workshops in Germany
  • Table 73 Germany: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 74 Germany: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 75 Germany: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 76 Germany: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 77 Germany: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 78 Germany: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 79 France: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 80 France: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 81 France: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 82 France: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 83 France: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 84 France: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 85 Italy: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 86 Italy: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 87 Italy: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 88 Italy: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 89 Italy: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 90 Italy: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 91 Spain: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 92 Spain: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 93 Spain: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 94 Spain: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 95 Spain: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 96 Spain: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 97 Switzerland: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 98 Switzerland: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 99 Switzerland: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 100 Switzerland: RWE solutions Market, by Application, 2022-2031 (USD Million)
  • Table 101 Switzerland: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 102 Switzerland: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 103 Belgium: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 104 Belgium: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 105 Belgium: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 106 Belgium: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 107 Belgium: RWE Solutions Market For Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 108 Belgium: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 109 Rest of Europe: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 110 Rest of Europe: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 111 Rest of Europe: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 112 Rest of Europe: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 113 Rest of Europe: RWE Solutions Market for Drug Development & Approvals, BY Therapeutic Area, 2022-2031 (USD Million)
  • Table 114 Rest of Europe: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 115 Asia-Pacific: RWE Solutions Market, by Country/Region, 2022-2031 (USD Million)
  • Table 116 Asia-Pacific: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 117 Asia-Pacific: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 118 Asia-Pacific: RWE Disparate Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 119 Asia-Pacific: RWE Solutions Market, By Application, 2022-2031 (USD Million)
  • Table 120 Asia-Pacific: RWE Market for Drug Development & Approvals, By Therapeutic Area, 2022-2031 (USD Million)
  • Table 121 Asia-Pacific: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 122 Japan: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 123 Japan: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 124 Japan: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 125 Japan: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 126 Japan: RWE Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 127 Japan: RWE Solutions Market by End User, 2022-2031 (USD Million)
  • Table 128 Diversified Real-world Data Sources in China
  • Table 129 China: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 130 China: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 131 China: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 132 China: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 133 China: RWE Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 134 China: RWE Solutions Market by End User, 2022-2031 (USD Million)
  • Table 135 India: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 136 INDIA: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 137 India: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 138 India: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 139 India: RWE Market for Drug Development & Approvals, By Therapeutic Area, 2022-2031 (USD Million)
  • Table 140 India: RWE Solutions Market by End User, 2022-2031 (USD Million)
  • Table 141 South Korea: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 142 South Korea: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 143 South Korea: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 144 South Korea: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 145 South Korea: RWE Market for Drug Development & Approvals, By Therapeutic Area, 2022-2031 (USD Million)
  • Table 146 South Korea: RWE Solutions Market by End User, 2022-2031 (USD Million)
  • Table 147 Australia: RWE Solutions Market, By Component, 2022-2031 (USD Million)
  • Table 148 Australia: RWE Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 149 Australia: RWE Disparate Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 150 Australia: RWE Solutions Market, By Application, 2022-2031 (USD Million)
  • Table 151 Australia: RWE Market for Drug Development & Approvals, By Therapeutic Area, 2022-2031 (USD Million)
  • Table 152 Australia: RWE Solutions Market by End User, 2022-2031 (USD Million)
  • Table 153 RWE Sources in Taiwan
  • Table 154 Taiwan: RWE Solutions Market, By Component, 2022-2031 (USD Million)
  • Table 155 TAIWAN: RWE Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 156 Taiwan: RWE Disparate Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 157 Taiwan: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 158 Taiwan: RWE Market for Drug Development & Approvals, By Therapeutic Area, 2022-2031 (USD Million)
  • Table 159 Taiwan: RWE Solutions Market by End User, 2022-2031 (USD Million)
  • Table 160 Currently, the Main Sources for Real-world Data (RWD) in Singapore are:
  • Table 161 Singapore: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 162 Singapore: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 163 Singapore: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 164 Singapore: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 165 Singapore: RWE Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 166 Singapore: RWE Solutions Market by End User, 2022-2031 (USD Million)
  • Table 167 Estimated Number of New Cancer Cases from 2022 vs 2025
  • Table 168 rest OF Asia-Pacific: RWE Solutions Market, By Component, 2022-2031 (USD Million)
  • Table 169 Rest of Asia-Pacific: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 170 Rest of Asia-Pacific: RWE Disparate Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 171 Rest of Asia-Pacific: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 172 Rest of Asia-Pacific: RWE Market for Drug Development & Approvals, By Therapeutic Area, 2022-2031 (USD Million)
  • Table 173 Rest of Asia-Pacific: RWE Market for Drug Development & Approvals, By End User, 2022-2031 (USD Million)
  • Table 174 Latin America: RWE Solutions Market, by Country/Region, 2022-2031 (USD Million)
  • Table 175 Latin America: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 176 Latin America: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 177 Latin America: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 178 Latin America: RWE Solutions Market, by application, 2022-2031 (USD Million)
  • Table 179 Latin America: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 180 Latin America: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 181 Brazil: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 182 Brazil: RWE Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 183 Brazil: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 184 Brazil: RWE Solutions Market, by Application, 2022-2031 (USD Million)
  • Table 185 Brazil: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 186 Brazil: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 187 Mexico: RWE Solutions Market Size, by Component, 2022-2031 (USD Million)
  • Table 188 Mexico: RWE Datasets Market Size, by Type, 2022-2031 (USD Million)
  • Table 189 Mexico: RWE Disparate Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 190 Mexico: RWE Solutions Market, By Application, 2022-2031 (USD Million)
  • Table 191 Mexico: RWE Solutions Market for Drug Development & Approvals, By Therapeutic Area, 2022-2031 (USD Million)
  • Table 192 Mexico: RWE Market for Drug Development & Approvals, By End User, 2022-2031 (USD Million)
  • Table 193 Rest of Latin America: RWE Solutions Market, By Component, 2022-2031 (USD Million)
  • Table 194 Rest of Latin America: RWE Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 195 Rest of Latin America: RWE Disparate Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 196 Rest of Latin America: RWE Solutions Market, By Application, 2022-2031 (USD Million)
  • Table 197 Rest of Latin America: RWE Solutions Market for Drug Development & Approvals, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 198 Rest of Latin America: RWE Solutions Market, by End User, 2022-2031 (USD Million)
  • Table 199 Middle East & Africa: RWE Solutions Market, by Component, 2022-2031 (USD Million)
  • Table 200 Middle East & Africa: RWE Datasets Market, By Type, 2022-2031 (USD Million)
  • Table 201 Middle East & Africa: RWE Disparate Datasets Market, by Type, 2022-2031 (USD Million)
  • Table 202 Middle East & Africa: RWE Solutions Market Size, By Application, 2022-2031 (USD Million)
  • Table 203 Middle East & Africa: RWE Solutions Market size For Drug Development & Approvals, By Therapeutic Area, 2022-2031 (USD Million)
  • Table 204 Middle East & Africa: RWE Solutions Market, By End User, 2022-2031 (USD Million)
  • Table 205 Recent Developments, By Company, 2021-2024

LIST OF FIGURES

  • Figure 1 Research Process
  • Figure 2 Secondary Sources Referenced For This Study
  • Figure 3 Primary Research Techniques
  • Figure 4 Key Executives Interviewed
  • Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
  • Figure 6 Market Sizing & Growth Forecast Approach
  • Figure 7 Global RWE Solutions Market, By Component, 2024 Vs. 2031 (USD Million)
  • Figure 8 Global RWE Solutions Market, By Application, 2024 Vs. 2031 (USD Million)
  • Figure 9 Global RWE Solutions Market, By End User, 2024 Vs. 2031 (USD Million)
  • Figure 10 RWE Solutions Market, By Geography 2024 Vs. 2031 (USD Million)
  • Figure 11 Impact Analysis of Market Dynamics
  • Figure 12 Personalized Medicines Approved of Total New Molecular Entities, 2015-2022 (%)
  • Figure 13 Share of Clinical Trials Conducted Between 2017-2021, By Region (%)
  • Figure 14 Global Real-World Solutions Market, By Component, 2024 Vs. 2031 (USD Million)
  • Figure 15 Global Real-World Solutions Market, By Application, 2024 Vs. 2031 (USD Million)
  • Figure 16 Global Real-World Solutions Market, By End User, 2024 Vs. 2031 (USD Million)
  • Figure 17 Global RWE Solutions Market, By Country/Region, 2024 Vs. 2031 (USD Million)
  • Figure 18 North America: RWE Solutions Market Snapshot
  • Figure 19 U.S: Number of Novel Drug Approvals (2016-2023)
  • Figure 20 Europe: RWE Solutions Market Snapshot
  • Figure 21 France: Share of Population Aged 65 and Above, 2017-2023
  • Figure 22 Spain: Pharmaceutical R&D Expenditure, 2019-2022 (USD Million)
  • Figure 23 Switzerland: Pharmaceutical R&D Expenditure, 2019-2022 (USD Million)
  • Figure 24 Pharmaceutical Production in Belgium, 2019-2022 (USD Million)
  • Figure 25 Asia-Pacific: Real-World Evidence Solutions Market Snapshot
  • Figure 26 Latin America: RWE Solutions Market Snapshot
  • Figure 27 Key Growth Strategies Adopted By Leading Players, 2021-2024
  • Figure 28 Real-World Evidence (RWE) Solutions Market: Competitive Benchmarking, by Component
  • Figure 29 Real-World Evidence (RWE) Solutions Market: Competitive Benchmarking, by Region
  • Figure 30 Competitive Dashboard: Real-World Evidence (RWE) Solutions Market
  • Figure 31 Market Share Analysis: Real-World Evidence (RWE) Solutions Industry, 2023
  • Figure 32 IQVIA Holdings, Inc.: Financial Overview (2023)
  • Figure 33 ICON plc: Financial Overview (2023)
  • Figure 34 Thermo Fisher Scientific, Inc.: Financial Snapshot (2023)
  • Figure 35 F. Hoffmann-La Roche Ltd.: Financial Snapshot (2023)
  • Figure 36 Oracle Corporation: Financial Snapshot (2023)
  • Figure 37 Elevance Health, Inc.: Financial Overview (2023)
  • Figure 38 Cognizant Technology Solutions Corporation: Financial Snapshot (2023)
  • Figure 39 Revvity, Inc.: Financial Snapshot (2023)
  • Figure 40 SAS Institute Inc.: Financial Snapshot (2023)